Clinical trial results:
A Multicenter, Double-Blind, Randomized, Parallel, Placebo Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 650 mg in Postsurgical Dental Pain

Summary

EudraCT number	2014-005278-12
Trial protocol	Outside EU/EEA
Global end of trial date	06 August 2010

Results information

Result version number	v2 (current)
This version publication date	07 September 2016
First version publication date	16 July 2015
Version creation reason	• New data added to full data set • Correction of full data set Bayer sponsor contact information to be updated

Trial information

Trial identification

Sponsor protocol code	BAY1019036/15082

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01122602
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser-Wilhelm-Allee, D-51368, Leverkusen, Germany,
Public contact	Clinical Trials Contact, Bayer AG, clinical-trials-contact@bayer.com
Scientific contact	Clinical Trials Contact, Bayer AG, clinical-trials-contact@bayer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 August 2010
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	06 August 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the analgesic efficacy of a single oral dose of fast release aspirin tablets, 650 milligram (mg) (2 × 325 mg) compared to regular aspirin tablets, 650 mg (2 × 325 mg) and placebo in subjects with post-surgical dental pain.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. This study was conducted according to the principles of the International Conference on Harmonisation harmonised tripartite guideline E6(R1): Good Clinical Practice, the World Medical Association Declaration of Helsinki and its most recent amendments, and United States Title 21 of the Code of Federal Regulations Parts 50 and 56 concerning informed consent and Institutional Review Board regulations. Before entering the study, the informed consent form was read by and explained to all subjects and/or their legally authorized representative. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 April 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 500
Worldwide total number of subjects	500
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	123
Adults (18-64 years)	377
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The trial was conducted at two study centers in the United States between 29 Apr 2010 (first subject first visit) and 06 August 2010 (last subject last visit).

Pre-assignment

Screening details:

A total of 500 subjects entered the study and were randomly assigned to 1 of 3 treatment groups; 497 subjects completed the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Data analyst, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)

Arm description:

Single oral dose of fast release aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 milliliter [mL]) between 1-4 hours post dental surgery.

Arm type	Experimental
Investigational medicinal product name	Acetylsalicyclic acid (Fast release Aspirin)
Investigational medicinal product code	BAY1019036
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Single oral dose of fast release aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 mL) between 1-4 hours post dental surgery.

Arm title	Acetylsalicyclic acid (Aspirin, BAYE4465)

Arm description:

Single oral dose of regular aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 mL) between 1-4 hours post dental surgery.

Arm type	Active comparator
Investigational medicinal product name	Acetylsalicyclic acid
Investigational medicinal product code	BAYE4465
Other name	Aspirin
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Single oral dose of regular aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 mL) between 1-4 hours post dental surgery.

Arm title	Placebo

Arm description:

Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.

Arm type	Placebo

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.

Number of subjects in period 1	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo
Started	200	200	100
Completed	200	199	98
Not completed	0	1	2
Consent withdrawn by subject	-	-	1
Adverse event	-	1	1

Baseline characteristics

Reporting groups	
Reporting group title	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Reporting group description:	
Single oral dose of fast release aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 milliliter [mL]) between 1-4 hours post dental surgery.	
Reporting group title	Acetylsalicyclic acid (Aspirin, BAYE4465)
Reporting group description:	
Single oral dose of regular aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 mL) between 1-4 hours post dental surgery.	
Reporting group title	Placebo
Reporting group description:	
Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.	

Reporting group values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo
Number of subjects	200	200	100
Age categorical			
Units: Subjects			
Age continuous			
Age continuous			
Units: years			
arithmetic mean	20.3	20.8	20.7
standard deviation	± 3.33	± 4.05	± 3.57
Gender categorical			
Gender categorical			
Units: subjects			
Female	137	117	66
Male	63	83	34
Baseline Pain Intensity by Categorical Scale			
Pain Intensity (PI) was rated by subjects on a 4-point categorical Pain Intensity Scale (0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain).			
Units: Subjects			
Moderate pain	114	111	56
Severe pain	86	89	44
Baseline Pain by 11-Point Pain Intensity			
When subjects indicated at least moderate pain, they were asked to score their pain on the 11-Point Numerical Pain Intensity Rating Scale (0 = no pain, 10 = very painful).			
Units: scores on a scale			
arithmetic mean	7.3	7.4	7.5
standard deviation	± 1.3	± 1.35	± 1.4

Reporting group values	Total		
Number of subjects	500		

Age categorical Units: Subjects			

Age continuous			
Age continuous			
Units: years arithmetic mean standard deviation	- -		
Gender categorical			
Gender categorical			
Units: subjects			
Female	320		
Male	180		
Baseline Pain Intensity by Categorical Scale			
Pain Intensity (PI) was rated by subjects on a 4-point categorical Pain Intensity Scale (0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain).			
Units: Subjects			
Moderate pain	281		
Severe pain	219		
Baseline Pain by 11-Point Pain Intensity			
When subjects indicated at least moderate pain, they were asked to score their pain on the 11-Point Numerical Pain Intensity Rating Scale (0 = no pain, 10 = very painful).			
Units: scores on a scale arithmetic mean standard deviation	- -		

End points

End points reporting groups

Reporting group title	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Reporting group description:	
Single oral dose of fast release aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 milliliter [mL]) between 1-4 hours post dental surgery.	
Reporting group title	Acetylsalicyclic acid (Aspirin, BAYE4465)
Reporting group description:	
Single oral dose of regular aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 mL) between 1-4 hours post dental surgery.	
Reporting group title	Placebo
Reporting group description:	
Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.	
Subject analysis set title	Safety analysis set (SAF) population
Subject analysis set type	Safety analysis
Subject analysis set description:	
SAF population included all randomized subjects who took at least 1 dose of the study drug.	
Subject analysis set title	Intent-to-treat (ITT) population
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
ITT population included all randomized subjects who took at least 1 dose of the study drug and who had at least 1 post-dose assessment on an efficacy parameter.	

Primary: Time to First Perceptible Pain Relief (PR)

End point title	Time to First Perceptible Pain Relief (PR)
End point description:	
The double-stopwatch method was used to record time to first perceptible PR. Time to first perceptible PR was defined as the duration from the subject taking the study drug until the subject first began to feel any pain-relieving effect from the study drug.	
End point type	Primary
End point timeframe:	
0 to 6 hours	

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[1]	200[2]	100[3]	
Units: minutes				
median (confidence interval 95%)	19.8 (18.23 to 20)	23.7 (19.2 to 30)	41.4 (30.68 to 103.9)	

Notes:

[1] - ITT population.

[2] - ITT population.

[3] - ITT population.

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Primary: Time to First Perceptible Pain Relief Confirmed	
End point title	Time to First Perceptible Pain Relief Confirmed

End point description:

The double-stopwatch method was used to record time to first perceptible PR confirmed. Time to first perceptible PR confirmed was defined as the duration from the subject taking the study drug until the first stopwatch was stopped as long as the subject stopped the second stopwatch at some later time or recorded either a PR score of at least 1 or a Pain Intensity Difference (PID) score of at least 1 at the next time point assessment. '99999' in the below table indicates data was not analysed as upper limit of 95 percent (%) confidence interval was not reached.

End point type	Primary

End point timeframe:

0 to 6 hours

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[4]	200[5]	100[6]	
Units: minutes				
median (confidence interval 95%)	19.8 (18.25 to 20.58)	27.1 (19.77 to 30.37)	57.6 (32.98 to 99999)	

Notes:

[4] - ITT population

[5] - ITT population

[6] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Secondary: Time to Meaningful Pain Relief

End point title	Time to Meaningful Pain Relief

End point description:

Meaningful pain relief was defined as when the subject felt the degree of pain relief was meaningful to

them. Time to meaningful pain relief was determined by a double-stopwatch measurement using Kaplan -Meier estimate, provided that the subject experienced both “perceptible” and “meaningful” pain relief. Those subjects who do not achieve meaningful pain relief after 6 hours after dosing or those who took rescue medication before experiencing meaningful pain relief was censored in the analysis. '99999' in the below table indicates, the median time to meaningful PR could not be calculated for the placebo group due to timing and number of censored observations.

End point type	Secondary

End point timeframe:

0 to 6 hours

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[7]	200[8]	100[9]	
Units: minutes				
median (confidence interval 95%)	48.9 (41.85 to 54.52)	119.2 (93.55 to 192.27)	99999 (99999 to 99999)	

Notes:

[7] - ITT population

[8] - ITT population

[9] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Secondary: Pain Intensity at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing

End point title	Pain Intensity at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing

End point description:

Pain intensity was evaluated using a 4-point Categorical Pain Intensity Rating Scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain) for all pain intensity assessments post-dose.

End point type	Secondary

End point timeframe:

10, 20, 30, 40, and 50 minutes and at 1, 2, 3, 4, 5, and 6 hours post-dose

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[10]	200[11]	100[12]	
Units: subjects				
10 minutes: No pain	0	0	0	
10 minutes: Mild pain	20	15	7	
10 minutes: Moderate pain	93	100	44	
10 minutes: Severe pain	87	85	49	
20 minutes: No pain	3	2	0	
20 minutes: Mild pain	32	30	10	
20 minutes: Moderate pain	107	89	41	
20 minutes: Severe pain	58	79	49	
30 minutes: No pain	11	2	0	
30 minutes: Mild pain	75	39	12	
30 minutes: Moderate pain	86	90	37	
30 minutes: Severe pain	28	69	51	
40 minutes: No pain	23	5	1	
40 minutes: Mild pain	101	55	16	
40 minutes: Moderate pain	60	80	36	
40 minutes: Severe pain	16	60	47	
50 minutes: No pain	38	7	1	
50 minutes: Mild pain	107	74	12	
50 minutes: Moderate pain	43	71	38	
50 minutes: Severe pain	12	48	49	
1 hour: No Pain	54	13	1	
1 hour: Mild Pain	100	76	10	
1 hour: Moderate Pain	35	63	35	
1 hour: Severe Pain	11	48	54	

2 hours: No Pain	33	24	0	
2 hours: Mild Pain	70	76	14	
2 hours: Moderate Pain	46	45	25	
2 hours: Severe Pain	51	55	61	
3 hours: No Pain	21	31	1	
3 hours: Mild Pain	62	64	18	
3 hours: Moderate Pain	44	40	21	
3 hours: Severe Pain	73	65	60	
4 hours: No Pain	24	30	3	
4 hours: Mild Pain	45	57	20	
4 hours: Moderate Pain	48	44	18	
4 hours: Severe Pain	83	69	59	
5 hours: No Pain	21	22	5	
5 hours: Mild Pain	39	56	19	
5 hours: Moderate Pain	48	48	17	
5 hours: Severe Pain	92	74	59	
6 hours: No Pain	20	21	5	
6 hours: Mild Pain	37	48	19	
6 hours: Moderate Pain	44	52	17	
6 hours: Severe Pain	99	79	59	

Notes:

[10] - ITT population

[11] - ITT population

[12] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1: 10 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.921
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 2: 10 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036) v Placebo
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.297
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 3: 10 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.32
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 4: 20 minutes postdose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.064
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 5: 20 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 6: 20 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.071
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 7: 30 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 8: 30 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 9: 30 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.004
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 10: 40 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 11: 40 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036) v Placebo
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 12: 40 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 13: 50 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 14: 50 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 15: 50 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 16: 1 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 17: 1 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 18: 1 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 19: 2 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.453
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 20: 2 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 21: 2 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 22: 3 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.17
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 23: 3 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 24: 3 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 25: 4 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.076
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 26: 4 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 27: 4 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 28: 5 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.059
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 29: 5 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.041
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 30: 5 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 31: 6 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.074
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 32: 6 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.122
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 33: 6 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	Cochran-Mantel-Haenszel

Secondary: Pain Intensity Difference (PID) at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing

End point title	Pain Intensity Difference (PID) at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing

End point description:

Pain intensity was evaluated using a 4-point Categorical Pain Intensity Rating Scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain) for all pain intensity assessments post-dose. For each post-dose time point, PID was derived by subtracting the pain intensity at the post-dose time point from the baseline intensity score (baseline score – post-baseline score). A positive difference was indicative of improvement.

End point type	Secondary

End point timeframe:
10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours post-dose

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[13]	200[14]	100[15]	
Units: units on a scale				
arithmetic mean (standard deviation)				
10 Minutes post-dose	0.1 (± 0.43)	0.1 (± 0.45)	0 (± 0.45)	
20 Minutes post-dose	0.3 (± 0.61)	0.2 (± 0.62)	0.1 (± 0.54)	
30 Minutes post-dose	0.8 (± 0.79)	0.3 (± 0.7)	0.1 (± 0.61)	
40 Minutes post-dose	1.1 (± 0.81)	0.5 (± 0.8)	0.2 (± 0.75)	
50 Minutes post-dose	1.3 (± 0.86)	0.7 (± 0.84)	0.1 (± 0.76)	
1 Hour post-dose	1.4 (± 0.91)	0.7 (± 0.9)	0 (± 0.75)	
2 Hours post-dose	0.9 (± 1.11)	0.8 (± 1.01)	0 (± 0.77)	
3 Hours post-dose	0.6 (± 1.08)	0.8 (± 1.07)	0.1 (± 0.8)	
4 Hours post-dose	0.5 (± 1.09)	0.7 (± 1.09)	0.1 (± 0.87)	
5 Hours post-dose	0.4 (± 1.06)	0.6 (± 1.03)	0.2 (± 0.91)	
6 Hours post-dose	0.3 (± 1.05)	0.5 (± 1.03)	0.2 (± 0.92)	

Notes:
[13] - ITT population
[14] - ITT population
[15] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1: 10 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.875
Method	ANCOVA

Statistical analysis title	Statistical analysis 2: 10 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.275
Method	ANCOVA

Statistical analysis title	Statistical analysis 3: 10 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.222
Method	ANCOVA

Statistical analysis title	Statistical analysis 4: 20 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.073
Method	ANCOVA

Statistical analysis title	Statistical analysis 5: 20 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 6: 20 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.026
Method	ANCOVA

Statistical analysis title	Statistical analysis 7: 30 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)

Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 8: 30 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 9: 30 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	ANCOVA

Statistical analysis title	Statistical analysis 10: 30 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 11: 40 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 12: 40 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 13: 50 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 14: 50 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 15: 50 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 16: 1 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)

Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 17: 1 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 18: 1 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 19: 2 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.456
Method	ANCOVA

Statistical analysis title	Statistical analysis 20: 2 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 21: 2 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 22: 3 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.106
Method	ANCOVA

Statistical analysis title	Statistical analysis 23: 3 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 24: 3 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 25: 4 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)

Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.049
Method	ANCOVA

Statistical analysis title	Statistical analysis 26: 4 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	ANCOVA

Statistical analysis title	Statistical analysis 27: 4 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 28: 5 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.048
Method	ANCOVA

Statistical analysis title	Statistical analysis 29: 5 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.057
Method	ANCOVA

Statistical analysis title	Statistical analysis 30: 5 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 31: 6 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.073
Method	ANCOVA

Statistical analysis title	Statistical analysis 32: 6 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.144
Method	ANCOVA

Statistical analysis title	Statistical analysis 33: 6 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.004
Method	ANCOVA

Secondary: Pain Relief at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing

End point title	Pain Relief at 10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours After Dosing

End point description:

Subjects rated pain relief on a 5-point categorical Pain Relief Rating Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).

End point type	Secondary

End point timeframe:

10, 20, 30, 40, 50, and 60 minutes and at 2, 3, 4, 5, and 6 hours post-dose

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[16]	200[17]	100[18]	
Units: subjects				
10 minutes: No relief	145	143	80	
10 minutes: Little relief	43	46	15	
10 minutes: Some relief	10	11	5	
10 minutes: Lot of relief	2	0	0	
10 minutes: Complete relief	0	0	0	
20 minutes: No relief	81	110	68	
20 minutes: Little relief	81	67	22	
20 minutes: Some relief	26	16	9	
20 minutes: Lot of relief	9	6	1	
20 minutes: Complete relief	3	1	0	
30 minutes: No relief	34	90	66	
30 minutes: Little relief	74	64	20	
30 minutes: Some relief	44	34	11	
30 minutes: Lot of relief	37	10	3	
30 minutes: Complete relief	11	2	0	
40 minutes: No relief	19	67	59	
40 minutes: Little relief	55	69	20	
40 minutes: Some relief	47	34	16	
40 minutes: Lot of relief	56	25	4	
40 minutes: Complete relief	23	5	1	
50 minutes: No relief	13	57	59	
50 minutes: Little relief	37	61	22	
50 minutes: Some relief	39	37	14	
50 minutes: Lot of relief	73	38	4	
50 minutes: Complete relief	38	7	1	
1 hour: No relief	13	53	57	
1 hour: Little relief	32	47	28	
1 hour: Some relief	30	44	10	
1 hour: Lot of relief	71	43	4	
1 hour: Complete relief	54	13	1	
2 hours: No relief	57	64	71	
2 hours: Little relief	29	22	12	
2 hours: Some relief	26	44	12	
2 hours: Lot of relief	55	46	5	
2 hours: Complete relief	33	24	0	
3 hours: No relief	83	75	71	

3 hours: Little relief	28	18	10	
3 hours: Some relief	20	35	8	
3 hours: Lot of relief	48	41	10	
3 hours: Complete relief	21	31	1	
4 hours: No relief	108	85	72	
4 hours: Little relief	14	19	5	
4 hours: Some relief	17	25	9	
4 hours: Lot of relief	37	41	11	
4 hours: Complete relief	24	30	3	
5 hours: No relief	117	96	73	
5 hours: Little relief	13	21	5	
5 hours: Some relief	14	20	9	
5 hours: Lot of relief	35	41	9	
5 hours: Complete relief	21	22	4	
6 hours: No relief	127	106	74	
6 hours: Little relief	8	15	5	
6 hours: Some relief	17	19	6	
6 hours: Lot of relief	28	39	11	
6 hours: Complete relief	20	21	4	

Notes:

[16] - ITT population

[17] - ITT population

[18] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1: 10 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.869
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 2: 10 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.168
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 3: 10 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.13
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 4: 20 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 5: 20 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 6: 20 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.045
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 7: 30 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 8: 30 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 9: 30 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 10: 40 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 11: 40 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 12: 40 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 13: 50 minutes post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 14: 50 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 15: 50 minutes post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 16: 1 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 17: 1 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 18: 1 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 19: 2 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.205
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 20: 2 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 21: 2 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 22: 3 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.233
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 23: 3 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 24: 3 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 25: 4 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.049
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 26: 4 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 27: 4 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 28: 5 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.101
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 29: 5 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.006
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 30: 5 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 31: 6 hours post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.067
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 32: 6 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.042
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 33: 6 hours post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Secondary: Summed Pain Intensity Differences (SPID) from Hour 0 through Hour 2, Hour 4 and Hour 6

End point title	Summed Pain Intensity Differences (SPID) from Hour 0 through Hour 2, Hour 4 and Hour 6

End point description:

Pain intensity was evaluated using a 4-point categorical Pain Intensity Rating Scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain) for all pain intensity assessments post-dose. Time-weighted SPID was calculated by multiplying the PID score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values for 0-2, 0-4, 0-6 hour intervals, respectively. The possible total score ranges of SPIDs are: SPID0-2: 0 to 6, SPID0-4: 0 to 12, SPID0-6: 0 to 18. The higher the SPID value, the more improvement of pain relief.

End point type	Secondary

End point timeframe:
0 - 6 hours post-dose

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[19]	200[20]	100[21]	
Units: units on a scale				
arithmetic mean (standard deviation)				
SPID 0 - 2	1.7 (± 1.6)	1.2 (± 1.51)	0.1 (± 1.19)	
SPID 0 - 4	2.8 (± 3.53)	2.7 (± 3.42)	0.3 (± 2.72)	
SPID 0 - 6	3.5 (± 5.4)	3.8 (± 5.29)	0.6 (± 4.45)	

Notes:
[19] - ITT population
[20] - ITT population
[21] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1: SPID 0-2
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 2: SPID 0-2
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 3: SPID 0-2
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 4: SPID 0-4
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.668
Method	ANCOVA

Statistical analysis title	Statistical analysis 5: SPID 0-4
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 6: SPID 0-4
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 7: SPID 0-6
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.631
Method	ANCOVA

Statistical analysis title	Statistical analysis 8: SPID 0-6
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 9: SPID 0-6
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Secondary: Summed Total Pain Relief (TOTPAR) from Hour 0 through Hour 2, Hour 4 and Hour 6

End point title	Summed Total Pain Relief (TOTPAR) from Hour 0 through Hour 2, Hour 4 and Hour 6

End point description:

Subjects rated pain relief on a 5-point categorical Pain Relief Rating Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).
TOTPAR was calculated by multiplying the pain relief score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values. The possible total score ranges of TOTPARs are: TOTPAR0-2: 0 to 6, TOTPAR0-4: 0 to 12, TOTPAR0-6: 0 to 18. The higher the LS Means scores, the more pain relief was obtained.

End point type	Secondary

End point timeframe:

0-6 hours post-dose

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[22]	200[23]	100[24]	
Units: units on a scale				
arithmetic mean (standard deviation)				
TOTPAR 0 - 2	3.6 (± 2.15)	2.7 (± 2.09)	1.1 (± 1.38)	
TOTPAR 0 - 4	6.3 (± 4.79)	6 (± 4.76)	2.3 (± 3.37)	
TOTPAR 0 - 6	8.5 (± 7.43)	8.6 (± 7.43)	3.7 (± 5.66)	

Notes:
[22] - ITT population
[23] - ITT population
[24] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1: TOTPAR 0-2
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 2: TOTPAR 0-2
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 3: TOTPAR 0-2
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 4: TOTPAR 0-4
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.437
Method	ANCOVA

Statistical analysis title	Statistical analysis 5: TOTPAR 0-4
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 6: TOTPAR 0-4
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 7: TOTPAR 0-6
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.875
Method	ANCOVA

Statistical analysis title	Statistical analysis 8: TOTPAR 0-6
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Statistical analysis title	Statistical analysis 9: TOTPAR 0-6
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA

Secondary: Time to First use of Rescue Medication

End point title	Time to First use of Rescue Medication

End point description:

Time to first use of rescue medication was estimated using the Kaplan-Meier method and analyzed by a log rank test stratified by trial site and baseline pain intensity (PI). The criteria were if adequate pain relief was not achieved, then subjects were permitted to take rescue medication. '99999' in the below table indicates data was not analysed as upper limit of 95% confidence interval was not reached.

End point type	Secondary

End point timeframe:

0 to 6 hours

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[25]	200[26]	100[27]	
Units: hours				
median (confidence interval 95%)	267.5 (227 to 307)	322 (252 to 99999)	104.5 (78 to 126)	

Notes:

[25] - ITT population

[26] - ITT population

[27] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.378
Method	Logrank

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Logrank

Secondary: Cumulative Percentage of Subjects Taking Rescue Medication

End point title	Cumulative Percentage of Subjects Taking Rescue Medication

End point description:

The cumulative percentage taking rescue medication by time point was analyzed using Chi-square tests.

End point type	Secondary

End point timeframe:

1, 2, 3, 4, 5, and 6 hours post-dose

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[28]	200[29]	100[30]	
Units: percentage of subjects				
number (not applicable)				
1 hour post-dose	0.5	2	6	
2 hour post-dose	13	20.5	57	
3 hour post-dose	31.5	31	68	
4 hour post-dose	43.5	38.5	72	
5 hour post-dose	52.5	45.5	72	
6 hour post-dose	59	51	72	

Notes:

[28] - ITT population

[29] - ITT population

[30] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1: 1 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.372
Method	Fisher exact

Statistical analysis title	Statistical analysis 2: 1 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.006
Method	Chi-squared

Statistical analysis title	Statistical analysis 3: 1 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.089
Method	Chi-squared

Statistical analysis title	Statistical analysis 4: 2 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.045
Method	Chi-squared

Statistical analysis title	Statistical analysis 5: 2 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Chi-squared

Statistical analysis title	Statistical analysis 6: 2 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Chi-squared

Statistical analysis title	Statistical analysis 7: 3 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.914
Method	Chi-squared

Statistical analysis title	Statistical analysis 8: 3 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Chi-squared

Statistical analysis title	Statistical analysis 9: 3 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Chi-squared

Statistical analysis title	Statistical analysis 10: 4 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.309
Method	Chi-squared

Statistical analysis title	Statistical analysis 11: 4 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Chi-squared

Statistical analysis title	Statistical analysis 12: 4 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Chi-squared

Statistical analysis title	Statistical analysis 13: 5 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.161
Method	Chi-squared

Statistical analysis title	Statistical analysis 14: 5 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	Chi-squared

Statistical analysis title	Statistical analysis 15: 5 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Chi-squared

Statistical analysis title	Statistical analysis 16: 6 hour post-dose
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.108
Method	Chi-squared

Statistical analysis title	Statistical analysis 17: 6 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.028
Method	Chi-squared

Statistical analysis title	Statistical analysis 18: 6 hour post-dose
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Chi-squared

Secondary: Global Assessment of the Investigational Product as a Pain Reliever at 6 hours After Dosing or Immediately Before the First Intake of Rescue Medication

End point title	Global Assessment of the Investigational Product as a Pain Reliever at 6 hours After Dosing or Immediately Before the First Intake of Rescue Medication

End point description:

Global assessment of the study drug as a pain reliever was analyzed using the Cochran-Mantel-Haenszel (CMH) test with modified ridit scores.
Categorical Scale: Poor (0), Fair (1), Good (2), Very Good (3), Excellent (4).

End point type	Secondary

End point timeframe:

At 6 hours postdose or immediately before first use of rescue medication

End point values	Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)	Acetylsalicyclic acid (Aspirin, BAYE4465)	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	200[31]	200[32]	100[33]	
Units: subjects				
Poor	39	58	60	
Fair	33	37	17	
Good	58	48	16	
Very good	44	39	5	
Excellent	25	16	0	

Notes:

[31] - ITT population

[32] - ITT population

[33] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Acetylsalicyclic acid (Aspirin, BAYE4465) v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)
Number of subjects included in analysis	400
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.013
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 2
Comparison groups	Placebo v Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)

Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Statistical analysis title	Statistical analysis 3
Comparison groups	Placebo v Acetylsalicyclic acid (Aspirin, BAYE4465)
Number of subjects included in analysis	300
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were recorded throughout the treatment period through 5 days after investigational product administration. All serious adverse events were collected through about 30 days after the last dose of investigational product or placebo.

Adverse event reporting additional description:

A treatment-emergent adverse event was defined as any adverse event that began after study drug administration, or any ongoing event that worsened in severity after study drug administration.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	12.1

Reporting groups

Reporting group title	Placebo

Reporting group description:

Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 1-4 hours post dentalsurgery.

Reporting group title	Regular Aspirin

Reporting group description:

Single oral dose of regular aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 mL)between 1-4 hours post dental surgery.

Reporting group title	Fast Release Aspirin

Reporting group description:

Single oral dose of fast release aspirin tablet 650 mg (2 x 325 mg) with a full glass of water (240 mL) between 1-4 hours post dental surgery.

Serious adverse events	Placebo	Regular Aspirin	Fast Release Aspirin
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	0 / 200 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Gastrointestinal disorders			
Gastritis			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo	Regular Aspirin	Fast Release Aspirin
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 100 (18.00%)	29 / 200 (14.50%)	29 / 200 (14.50%)
Injury, poisoning and procedural complications			
Operative haemorrhage			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	1 / 200 (0.50%)
occurrences (all)	0	1	1
Post procedural haemorrhage			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Procedural site reaction			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	1 / 200 (0.50%)
occurrences (all)	0	1	1
Nervous system disorders			
Dizziness			
subjects affected / exposed	3 / 100 (3.00%)	3 / 200 (1.50%)	4 / 200 (2.00%)
occurrences (all)	3	3	5
Headache			
subjects affected / exposed	1 / 100 (1.00%)	8 / 200 (4.00%)	1 / 200 (0.50%)
occurrences (all)	1	9	1
Hypoaesthesia			
subjects affected / exposed	1 / 100 (1.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Migraine			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	0 / 200 (0.00%)
occurrences (all)	0	1	0
Somnolence			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	0 / 200 (0.00%)
occurrences (all)	0	1	0
Syncope			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	1 / 200 (0.50%)
occurrences (all)	0	1	1
Ear and labyrinth disorders			

Ear pain			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Eye disorders			
Eye pruritus			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	0 / 200 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 100 (1.00%)	2 / 200 (1.00%)	0 / 200 (0.00%)
occurrences (all)	1	2	0
Diarrhoea			
subjects affected / exposed	1 / 100 (1.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Hypoaesthesia oral			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Dysphagia			
subjects affected / exposed	1 / 100 (1.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	1 / 100 (1.00%)	2 / 200 (1.00%)	3 / 200 (1.50%)
occurrences (all)	1	2	3
Nausea			
subjects affected / exposed	6 / 100 (6.00%)	5 / 200 (2.50%)	9 / 200 (4.50%)
occurrences (all)	6	5	9
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1

Oropharyngeal pain			
subjects affected / exposed	1 / 100 (1.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	1 / 100 (1.00%)	1 / 200 (0.50%)	1 / 200 (0.50%)
occurrences (all)	1	1	1
Pleuritic pain			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Hypoaesthesia facial			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	1 / 200 (0.50%)
occurrences (all)	0	1	1
Pruritus			
subjects affected / exposed	1 / 100 (1.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Pruritus generalised			
subjects affected / exposed	1 / 100 (1.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	1 / 100 (1.00%)	0 / 200 (0.00%)	0 / 200 (0.00%)
occurrences (all)	1	0	0
Pain in jaw			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	0 / 200 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Alveolar osteitis			
subjects affected / exposed	3 / 100 (3.00%)	6 / 200 (3.00%)	6 / 200 (3.00%)
occurrences (all)	3	6	6
Abscess jaw			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	0 / 200 (0.00%)
occurrences (all)	0	1	0

Postoperative abscess			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1
Postoperative wound infection			
subjects affected / exposed	0 / 100 (0.00%)	1 / 200 (0.50%)	1 / 200 (0.50%)
occurrences (all)	0	1	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 100 (0.00%)	0 / 200 (0.00%)	1 / 200 (0.50%)
occurrences (all)	0	0	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 April 2010	This amendment added physical examination and urine drug screen assessments.
14 June 2010	This amendment clarified inclusion criterion for removal of 2 versus 4 teeth.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

'99999' in the posting indicates that data was not available. Decimal places were automatically truncated if last decimal equals zero.

Notes: